"MD Anderson Madrid es en la actualidad centro de referencia y de excelencia para el tratamiento del cáncer en España y en Europa gracias a un equipo de profesionales altamente especializados, a las magníficas instalaciones actuales y a la continua y estrecha colaboración con MD Anderson Cancer Center de Houston. Además, MD Anderson Madrid cuenta entre sus profesionales con equipos de investigación de talla internacional lo que nos permite ofrecer a nuestros pacientes los últimos avances en el tratamiento y diagnóstico del cáncer."

During the past decade, MD Anderson Cancer Center conducted 139 clinical trials. In the 10-year time frame, 139 clinical trials started and 58 clinical trials were completed, i.e. on average, 41.7% percent of trials that started reached the finish line to date. In the past 5 years, 61 clinical trials started and 41 clinical trials were completed. i.e. 67.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "MD Anderson Cancer Center" #1 sponsor was "Hoffmann-La Roche" with 17 trials, followed by "Pfizer" with 11 trials sponsored, "Daiichi Sankyo, Inc." with 9 trials sponsored, "PharmaMar" with 6 trials sponsored and "Genmab" with 6 trials sponsored. Other sponsors include 135 different institutions and companies that sponsored additional 91 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "MD Anderson Cancer Center" #1 collaborator was "AstraZeneca" with 8 trials as a collaborator, "Merck Sharp & Dohme LLC" with 7 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 5 trials as a collaborator, "Astellas Pharma Inc" with 4 trials as a collaborator and "BioNTech SE" with 4 trials as a collaborator. Other collaborators include 103 different institutions and companies that were collaborators in the rest 86 trials.

According to Clinical.Site data, the most researched conditions in "MD Anderson Cancer Center" are "Breast Cancer" (20 trials), "Ovarian Cancer" (10 trials), "Metastatic Breast Cancer" (8 trials), "Fallopian Tube Cancer" (7 trials) and "Epithelial Ovarian Cancer" (6 trials). Many other conditions were trialed in "MD Anderson Cancer Center" in a lesser frequency.

Most popular intervention types in "MD Anderson Cancer Center" are "Drug" (165 trials), "Biological" (16 trials), "Procedure" (8 trials), "Other" (7 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (22 trials), "Placebo" (21 trials), "Carboplatin" (13 trials), "Pembrolizumab" (12 trials) and "Docetaxel" (11 trials). Other intervention names were less common.

The vast majority of trials in "MD Anderson Cancer Center" are 138 trials for "All" genders, 44 trials for "Female" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "MD Anderson Cancer Center". undefined are not yet recruiting, 44 are recruiting, 41 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 82 completed trials in MD Anderson Cancer Center, 2 suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in MD Anderson Cancer Center, 34 "Phase 1" clinical trials were conducted, 73 "Phase 2" clinical trials and 72 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 5 trials that are defined as “Not Applicable".

MD Anderson Cancer Center has several departments that took part in Clinical trials: "MD Anderson Cancer Centre Madrid" - 6 trials